Ongoing Pelareorep Clinical Studies

Programs Combination Indication Preclinical Phase 1 Phase 2 Phase 3 Milestone
Breast Cancer
BRACELET-1
Bavencio HR+/HER2-mBC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
ORR, PFS, evolving OS H1 '23
AWARE-1
Tecentriq HR+/HER2-BC
Window of Opportunity Study Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

Final Data Q4 '22

IRENE
Retifanlimab* (TNBC)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Phase 2 Safety Data Q4 '21

Gastro-Intestinal Cancer
GOBLET
Tecentriq 1L Adv/Metastatic Pancreatic Cancer
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Interim Data Q4 '22

GOBLET
Tecentriq 1L# mCRC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

-

GOBLET
Tecentriq 3L mCRC
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Safety run-in Complete

GOBLET
Tecentriq 2L Unresectable Anal Cancer
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

-

*Anti-PD-1 checkpoint inhibitor in development by Incyte (also known as INCMGA00012); mBC: Metastatic Breast Cancer; BC: Breast Cancer; ORR: Overall Response Rate; PFS: Progression-Free Survival, OS: Overall Survival; TNBC: Triple-Negative Breast Cancer; Adv: Advanced; L: Line; 1L#: First-line MSI-high focused; mCRC: Metastatic Colorectal Cancer